A n A ly s i s
Whole exome sequencing by high-throughput sequencing of target-enriched genomic DNA (exome-seq) has become common in basic and translational research as a means of interrogating the interpretable part of the human genome at relatively low cost. We present a comparison of three major commercial exome sequencing platforms from Agilent, Illumina and Nimblegen applied to the same human blood sample. Our results suggest that the Nimblegen platform, which is the only one to use high-density overlapping baits, covers fewer genomic regions than the other platforms but requires the least amount of sequencing to sensitively detect small variants. Agilent and Illumina are able to detect a greater total number of variants with additional sequencing. Illumina captures untranslated regions, which are not targeted by the Nimblegen and Agilent platforms. We also compare exome sequencing and whole genome sequencing (WGS) of the same sample, demonstrating that exome sequencing can detect additional small variants missed by WGS.
It is now possible to analyze the genomic DNA of individuals using whole genome sequencing and exome sequencing [1] [2] [3] , and these strategies have become popular for basic 4, 5 and translational [6] [7] [8] [9] [10] [11] research. Exome sequencing involves the capture of RNA coding regions by hybridizing genomic DNA to oligonucleotide probes (baits) that collectively cover the human exome regions. These enriched genomic regions are then sequenced using high-throughput DNA sequencing technology 12 . Although WGS is more comprehensive, exome sequencing has become more common because it captures the highly interpretable coding region of the genome and is more affordable, thereby allowing large numbers of samples to be analyzed. Exome sequencing has been used for analyses of disease loci that segregate in families 13, 14 , large disease cohorts (National Heart, Lung, and Blood Institute) and validation in WGS studies (such as The 1000 Genomes Project 15 ).
There are currently three major exome enrichment platforms: Agilent's SureSelect Human All Exon 50Mb, Roche/Nimblegen's SeqCap EZ Exome Library v2.0 and Illumina's TruSeq Exome Enrichment. Each platform uses biotinylated oligonucleotide baits complementary to the exome targets to hybridize sequencing libraries prepared from fragmented genomic DNA. These bound libraries are enriched for targeted regions by pull-down with magnetic streptavidin beads and then sequenced. The technologies differ in their target choice, bait lengths, bait density and molecule used for capture (DNA for Nimblegen and Illumina, and RNA for Agilent). The performance of each technology was systematically analyzed and compared, thereby revealing how design differences and experimental parameters (e.g., sequencing depth) affect variant discovery.
RESULTS

Platform design differences
There are substantial differences in the density of oligonucleotide baits between the three platforms (Fig. 1a) . Nimblegen contains overlapping baits that cover the bases it targets multiple times, making it the highest density platform of the three. Agilent baits reside immediately adjacent to one another across the target exon intervals. Illumina relies on paired-end reads to extend outside the bait sequences and fill in the gaps.
The exome enrichment platforms also have different target regions. The exome consists of all the exons of a genome that are transcribed into mature RNA. Numerous databases of mRNA coding sequences exist (including RefSeq 16 , UCSC KnownGenes 17 and Ensembl 18 ). They contain different numbers of noncoding RNA genes, and the start and end positions of some transcripts differ between them. Each commercial platform targets particular exomic segments based on combinations of the available databases. We compared the exact regions of the genome covered by each platform (based on individual design documents obtained from the company websites or through correspondence) (Fig. 1b) . A large number of bases (29.45 We first examined coverage of major RNA databases-RefSeq (coding and untranslated region (UTR)), Ensembl (total and coding sequence (CDS)) and the microRNA (miRNA) database miRBase 19 (Supplementary Table 1 ). Coverage of mRNA coding exons in both RefSeq (Fig. 1c) and Ensembl (Fig. 1d) was strikingly similar between all platforms. The shared bases in mRNA coding exons account for nearly all of the 29.45 Mb common to the three platforms. Nonetheless, each platform does target specific regions. The majority of the Illumina-specific 27.73 Mb targets UTR regions (Fig. 1e) . Nimblegen covers a greater portion of miRNAs, and Agilent better covers Ensembl genes.
A n A ly s i s
Various metrics from the physical protocols for each platform were compared (Supplementary Table 2 ). Input genomic DNA ranged from 1 µg (Illumina) to 3 µg (Nimblegen and Agilent). The total procedure time before sequencing ranged from 3.5 d (Agilent, Illumina) to 7 d (Nimblegen). Pre-and post-hybridization PCR cycles varied across platforms. Agilent uses RNA in its selection rather than DNA. All three platforms can be automated. Although the list price for each platform varies, the per-reaction prices are highly negotiable with the vendors and currently range from <$400 to >$1,000.
Target enrichment efficiency
To assess the enrichment efficiency of each platform, we sequenced libraries generated from genomic DNA derived from peripheral blood mononuclear cells (PBMCs) of a healthy volunteer of European descent. Exome DNA was enriched with each platform according to the manufacturers' recommendation. For each exome library, 112-184 million (M) 101-bp paired-end reads were generated using one lane of an Illumina HiSeq 2000 and mapped using the Burrows-Wheeler Alignment tool (BWA). BWA mapped 99% of reads to human DNA (with 88-95% to unique regions of the genome), and 10-15% of those reads were duplicates (PCR artifacts) that were removed during postprocessing (Supplementary Table 3 ). For comparison at constant read depth, 80M mapped reads were randomly drawn from each data set.
Overall targeting efficiency was assessed by measuring base coverage over all targeted bases for each platform at 80M reads. With Nimblegen enrichment, 98.6% of the targeted bases were covered at least once, and 96.8% at ≥10×; with Illumina, 97.1% of bases were covered at least once, and 90.0% at ≥10×; with Agilent, 96.6% of bases were covered at least once, and 89.6% at ≥10× (Fig. 2a) .
To assess targeting and enrichment efficiency as a function of sequencing depth, we randomly chose aligned reads from the 80M read pool in 10M read increments from 20-80M reads. The percent of targeted bases covered at depths of at least 10×, 20× and 30× were assessed (Fig. 2b-d) . At all read counts and depth cut-offs, the Nimblegen platform enriched a higher percentage of its targeted bases than the other two platforms. Illumina and Agilent enriched a higher total number of bases at higher read counts (Fig. 2e-g ). The efficient baits became saturated by 40M (Nimblegen), 50M (Agilent) and 60M (Illumina) reads, with <2% increase in bases covered at ≥10×. These findings indicate that design differences dramatically affect the balance between targeting efficiency and total number of bases targeted. A higher density design, targeting a smaller genomic interval, results in higher efficiency. Lower density designs can capture a greater total number of bases but require substantially larger amounts of sequencing.
Off-target enrichment
Off-target regions may be enriched if there is high sequence similarity between those regions and bait regions. The number of reads that unambiguously mapped to regions outside the targeted bait intervals for each platform (±500 bp) was quantified in the normalized 80M read data sets to assess off-target enrichment; 9.3% of Nimblegen, 12.8% of Agilent and 35.6% of Illumina reads uniquely mapped to off-target regions (Fig. 3a) . The percent of off-target enrichment correlated strongly with the enrichment trends mentioned previously, suggesting that off-target enrichments have a dramatic effect on targeting efficiency. Off-target reads were cross-referenced with RepeatMasker and segmental duplications, genomic structures known to confound targeted assays. For all three platforms, a higher fraction of off-target enrichments mapped to repeat elements (Fig. 3b) and segmental duplications (Fig. 3c) than did on-target regions.
Enrichment bias owing to GC content
Another source of potential inefficiency may come from targeting regions with high or low GC content. Lower coverage in sequencing regions with high GC or high AT content has long been observed 20 . GC bias in sequencing studies is in large part due to early PCR steps during library generation 21 where high and low GC content cause reduced amplification and therefore lower sequencing coverage. GC content has also been shown to affect the efficiency of hybridization to oligonucleotides 22, 23 , and therefore may also influence target enrichment by oligonucleotide baits. To investigate the effect of GC content on efficiency, we plotted GC content against mean read depth across target regions using the normalized 80M-read data sets ( Fig. 3d-f) . The density plots show that each platform demonstrates a marked reduction in read depth over high and low GC targets. All three platforms showed a sharp drop in read depth as GC content increased from 60% to 80%. As the GC content dropped from 40% to 20%, the performance of both Nimblegen and Illumina diminished with lower read depth over those targets (Fig. 3e,f) . The Agilent platform displayed only a slight reduction in read depth across low GC targets (Fig. 3d) , possibly because of its lower number of PCR cycles, longer baits and/or the use of RNA probes.
Detection of single-nucleotide variations
Although enrichment efficiency is a function of read depth, it does not necessarily correlate with ability to identify variants. Singlenucleotide variations (SNVs) represent the most numerous sequence variations in the human exome 15 and their accurate and comprehensive identification is a major goal of exome sequencing. To evaluate Table 4) . Single-nucleotide polymorphism (SNP) calls were validated by analyzing the same sample with Illumina Human 1M-Duo SNP Chip. Data were restricted to bases within the targeted regions that received a Phred-based quality score ≥30 by GATK. Heterozygous positions in the SNP Chip were compared to the genotype calls in the normalized 80M read exome sequencing data. Concordance rates were 99.3% for Agilent, 99.5% for Nimblegen and 99.2% for Illumina. For each platform, all nonconcordant genotype calls were calls of homozygous reference. Reference bias is a phenomenon often observed in sequencing studies 25 . Allelic balance (AB) was calculated by determining the ratio of reference base calls over the total number of calls at every SNV with a quality score ≥30. For Agilent, AB = 0.55, for Nimblegen and Illumina, AB = 0.53. These biases were not strong, but explain a fraction of the discordance with the SNP Chip data. SNP Chips also have their own error rates that may account for some of the discordance.
Trends in SNV calls
In general, although the oligonucleotides, bait length and type (DNA and RNA) differ, no biases toward or against specific nucleotide substitutions were observed among the three platforms. There was a slight increase in G→A/C→T transitions and slight decrease in non-G→C/C→G transversions in the Nimblegen data because a larger percent of its target bases are in coding regions, which have a higher GC content and therefore different nucleotide substitution rates from the rest of the genome 26 . The transition/transversion (ts/tv) ratio of total variants ranged from 2.53 to 2.67 and was slightly lower than estimates of ~2.8 from the exome based on 1000 Genomes data 15 . As expected, the platform with the most target sequence outside coding exons (Illumina) had the lowest ts/tv, whereas the platform with the least (Nimblegen) had the highest. No significant difference in the ratio of heterozygous to homozygous variants between platforms was observed.
We next examined whether the differences in efficiency at lower read counts affected overall SNV detection. For all platforms, the total number of SNVs detected increased as read count increased (Fig. 4a) . There was a correlation between the total bases targeted by the platform and the number of SNVs detected, particularly at higher read counts. This increase was not linear, and for more than 30M reads, fewer than 5% additional SNVs were found by increasing read depth. SNV detection across targeted bases shared by all three platforms was assessed (Fig. 4b) . In shared regions, Nimblegen consistently captured the most SNVs and became saturated with the lowest number of reads, followed by Agilent and then Illumina, indicating a correlation between bait density and sensitivity to SNV detection. A n A ly s i s SNV detection in mRNA coding regions SNV detection in regions covered by particular exome databases was examined. Nimblegen-enriched libraries consistently enabled detection of the greatest number of RefSeq coding region variants at every read count (Fig. 4c) . Illumina enrichment detected many more mutations in the UTR than either Agilent or Nimblegen (Fig. 4d) . By 30M reads, Agilent's additional coverage allowed it to identify the most Ensembl CDS SNVs (Fig. 4e) .
Variants specifically detected by one platform were examined in more detail. Platform-specific SNVs were typically discovered because of higher coverage in their targeted regions. The higher efficiency of Nimblegen's dense baits led to higher relative coverage of low complexity, hard-to-target regions and therefore detection of more SNVs in these regions (Supplementary Fig. 1a) . Agilent detected unique SNVs most often in introns because Agilent baits sometimes extend farther outside the exon targets than the baits of other platforms (Supplementary Fig. 1b) . Most of the SNVs detected uniquely by Illumina lie in UTRs (Supplementary Fig. 1c ).
Small insertion and deletion detection
Small insertions and deletions (indels), ranging in size from −84 to +18 bases, were detected at a frequency of 12.5-14.5% that of SNVs (Supplementary Data 2 and Supplementary Table 4), similar to the percentage reported by others 15, 26 . As with SNVs, the total number of indels detected correlated with read count (Fig. 5a) . Notably, at low read counts, more indels were detected after Agilent enrichment than after Illumina enrichment. At 50M reads, Illumina surpassed Agilent.
Coverage of regions containing indels largely matched coverage over the targeted regions. In shared and RefSeq regions, Nimblegen had the highest sensitivity for detecting indels because of higher average read depth. Agilent surpassed Illumina in indel detection at low read counts (Fig. 5b,c) . Many more indels in UTRs were detected after Illumina enrichment (Fig. 5d) . Agilent enrichment led to the largest number of detected indels at every read count in Ensembl CDS exons (Fig. 5e) .
Most indels were 1 base in size (Supplementary Fig. 2a) . Notably, there were slight enrichments at indel sizes of 4 and 8 bases in the total captured DNA data, consistent with findings in comparisons between human and primate genomes 27 . As expected 28 , the frequency of indels present in the protein coding segments was much lower than in the total covered regions, which contain introns, UTRs and intergenic sequences (Supplementary Fig. 2b ). There was a strong bias toward indels of a size equal to multiples of three bases in coding regions. This pattern was presumably due to selective pressure against deleterious frameshift mutations in the coding regions.
Comparison with WGS
WGS requires a much greater amount of sequencing to achieve equivalent coverage as exome sequencing, but its performance relative to exome sequencing has not been well described. To do such a comparison, we performed WGS to high read depth on an Illumina HiSeq 2000 on a blood sample from the same individual analyzed for the exome sequencing comparison. A subset of those reads (seven lanes) was extracted, mapped and had duplicates removed. This yielded 1,194,622,756 unambiguously mapped, nonduplicate 10-bp paired-end reads and a mean 35× genome-wide coverage. To compare this level of coverage to what can be obtained using exome sequencing, we normalized our exome sequencing data to 50M reads for each platform because this level allows multiplexing at least 3 and up to 6 exomes per lane. The resulting coverage for each platform was 30× mean target coverage for Illumina, 60× for Agilent and 68× for Nimblegen. Thus, using <5% of the number of unambiguously mapped reads, exome sequencing achieved coverage over targets that was in one case nearly equal to (Illumina) and in the two others almost two times as high as (Agilent and Nimblegen) that of WGS.
Sensitivity for detecting SNVs was compared between WGS and the exome sequencing experiments. Variants were called from the WGS data using GATK with the same cut-offs and filters as exome sequencing. The WGS data had 98.5% concordance with SNP Chip at heterozygous positions. The WGS data were restricted to the regions targeted by each platform for comparison. The majority of SNVs were detected by both exome sequencing and WGS across all three platforms, but there were both exome sequencing-specific and WGSspecific SNVs (Supplementary Table 5 ).
The average Phred-based quality scores for SNVs from exome sequencing were much higher than those of SNVs from WGS for Nimblegen (573 in exome versus 320 in WGS) and Agilent (428 versus 192), and very close for Illumina (341 versus 380). The exome sequencing-and WGS-specific SNVs had lower average quality than those SNVs detected by both. A greater proportion of WGS-specific SNVs were of a low quality compared to exome sequencing-specific SNVs for Agilent and Nimblegen (Supplementary Fig. 3a,b) . For Illumina, exome sequencing-and WGS-specific SNV qualities were very similar (Supplementary Fig. 3c ). This was because 50M reads only generate 30× coverage by Illumina exome sequencing. A n A ly s i s Therefore, Illumina was compared again at 60M, 70M and 80M reads yielding coverages of 36×, 42× and 48×, respectively. The quality of all variants increased accordingly, as did the quality of exome sequencingspecific variants.
As variant quality scores are closely tied to read depth over the variant positions, we compared coverage between exome sequencing and WGS over variant positions. Variants detected uniquely by exome sequencing or WGS did indeed have greater average coverage in their detection platform as compared with the total variants detected by both (Fig. 6a-c) . The WGS-specific SNVs often had zero coverage by exome sequencing (169 Nimblegen SNVs with zero coverage out of 1,235; 615 Agilent SNVs out of 3,362; 2,275 Illumina SNVs out of 6,126), suggesting enrichment failure in these regions. In contrast, very few of the exome sequencing-specific SNVs had zero coverage in WGS (14 Nimblegen-specific SNVs out of 2,291; 13 Agilent-specific SNVs out of 5,199; 24 Illumina-specific SNVs out of 4,385). However, these exome sequencing-specific SNVs tended to have lower than average base coverage in WGS. This even held true for the Illumina exome sequencing at 30× mean coverage relative to WGS. These results indicate that enrichment is capable of bolstering coverage at specific positions that are missed by WGS and leads to more sensitive variant calling in those regions.
To determine as precisely as possible the number of true exome sequencing-specific and WGS-specific SNVs, we estimated the quantity of false-positive SNVs for each experiment. Based on the assumption that SNVs detected by both exome sequencing and WGS (hereafter called shared SNVs) are highly robust, novel variant rates were estimated by comparing shared SNVs with known common SNPs (>1% allele frequency in the population according to dbSNP132). Considering shared SNVs, 13.3% (4,704/35,448) of Agilent's, 11.2% (3,385/30,097) of Nimblegen's and 12.1% (5,151/42,633) of Illumina's were novel by this definition. The novel variant rates were significantly (P < 10 −16 ) higher in the exome sequencing-specific SNVs (60.3% of Agilent's, 39.3% of Nimblegen's, 48.9% of Illumina's) and WGS-specific SNVs (56.2% of Agilent's, 59.8% of Nimblegen's, 34.6% of Illumina's), suggesting large quantities of false-positive SNVs in these sets. False positives were estimated by calculating the expected number of novel SNVs in the experiment-specific sets based on the Figure 5 Sensitivity toward indels compared between each platform at increasing read counts. Indel sensitivity may be more intimately tied to factors such as bait length and density compared with SNV sensitivity. (a) Total number of indels detected at increasing read count thresholds. As with SNVs, sensitivity increases at higher read counts. Agilent detects the highest quantity at lower read counts because its baits appear more robust toward indels than Illumina's.
(b) Indels detected in bases targeted by all three platforms. Nimblegen detects the most indels at all read counts because it is the most efficient. Very few indels are detected in the shared interval because it is mostly made up of coding exons, which have a strong bias against indels. (c) Indels detected in RefSeq coding exons. These curves match the shared interval curves from b closely, much like for SNVs. (d) Indels detected in RefSeq UTRs. Again, Illumina detects far more of these because it is the only platform that specifically targets UTRs. (e) Indels detected in Ensembl CDS. Agilent detects the most indels in Ensembl CDS due to a combination of the additional 1.4 Mb of targeted Ensembl CDS bases and its high sensitivity toward indels.
A n A ly s i s number of known SNPs. We detected 2,799 Agilent, 2,561 Nimblegen and 3,146 Illumina exome sequencing-specific SNVs and 1,699 Agilent, 653 Nimblegen and 4,560 WGS-specific SNVs (Fig. 6d-f) . The false-positive SNV sets generally have low quality scores, so using a higher quality score threshold on these variants recovers most of the true-positive novel SNVs. These data demonstrate that there are some regions (and therefore variants) that are missed by a typical WGS but observed by exomesequencing enrichment because of the higher coverage attainable with target-enriched sequencing over specific regions. Similarly, there are some targeted regions and variants missed by each exome sequencing platform but detected by WGS. Comparison with a large database of disease-related variants 29, 30 classified 456 Agilent, 369 Nimblegen and 467 Illumina exome sequencing-specific SNVs as associated with human diseases. Three hundred and one of these were common between all three platforms, suggesting that some regions missed by WGS but captured by exome sequencing have clinical relevance.
DISCUSSION
A comparison study such as this one is intended to inform the research community of the pros and cons of each platform and to help investigators make an informed decision about which platform is best for their research. In this case, all three exome enrichment platforms demonstrate a very high level of targeting efficiency and cover a very large portion of the overall exome. The question of which enrichment platform is best must be answered with respect to specific parameters. We have observed that the densely packed, overlapping baits of the Nimblegen SeqCap EZ Exome demonstrate the highest efficiency target enrichment, able to adequately cover the largest proportion of its targeted bases with the least amount of sequencing. Therefore, the Nimblegen platform is superior to the other two platforms for research restricted to the regions that it covers.
However, greater genomic coverage is desirable to many researchers. The per-base cost of sequencing is plummeting 31 , and as a result the optimal balance between efficiency and coverage is changing. As sequencing becomes cheaper, efficiency often becomes less valuable relative to coverage. We have detailed the regions of the genome uniquely covered by each platform because particular regions targeted by one platform may be of interest to specific researchers. Although the Illumina platform demonstrated less targeting efficiency than the others, it is the only platform that is designed to enrich UTRs, which are almost completely untargeted by the other two platforms, and is therefore the natural choice for researchers interested in those regions.
Many researchers performing exome sequencing are most interested in coding regions. Although coding regions can be difficult to define because they differ depending on the database used, the main goal of exome sequencing is discovering variations associated with particular phenotypes. Exomes are particularly powerful for research on Mendelian disorders, as these disorders are often caused by small mutations in gene coding regions. Our results suggest that with regard to the RefSeq exome, Nimblegen has a slight edge in sensitivity for SNPs and small indels. However, with regard to the Ensembl CDS regions, the Agilent SureSelect Human All Exon kit can detect the most SNPs and small indels given slightly more sequencing. All of these platforms can detect disease-associated variants, of which a small proportion are unique to each platform.
Our findings with exome sequencing can be extended to general enrichment principles and custom enrichment assays. We demonstrated multiple levels of bait density and genome coverage that can be used as a guide when designing custom enrichment bait sets. Although it is evident that overlapping baits improved sensitivity, the number of overlapping baits that are necessary remains unclear. What is clear is that an overlapping design is superior to an immediately adjacent or spaced design with regard to enrichment efficiency. Moreover, we observed that the relatively long baits and/or RNA methodology of the Agilent SureSelect allowed for increased sensitivity toward indels. Therefore, longer baits of this type are more desirable in custom assay designs.
It may be argued that the importance of targeted sequencing is transient and will diminish as WGS becomes less expensive. However, we found that exome sequencing can identify variants that are not evident in WGS because of greater base coverage after enrichment. Even at equivalent coverage levels, specific regions had higher read depth in exome sequencing resulting in greater sensitivity in those regions. Target capture by exome sequencing unambiguously identified some of these difficult regions through preferential selection and observation at higher local read depth. These findings demonstrate a strong niche for target enrichment approaches even after WGS sequencing, where targeted sequencing is used to clarify results in regions where WGS yields low depth of coverage, to validate personal variations and to bolster discovery in the most interpretable part of the human genome.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/. Accession code. Exome sequencing and whole-genome sequencing data are available at the Sequence Read Archive under accession SRA040093.
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